vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Vanda Pharmaceuticals Inc. is the larger business by last-quarter revenue ($57.2M vs $30.1M, roughly 1.9× Dominari Holdings Inc.). Vanda Pharmaceuticals Inc. runs the higher net margin — -246.8% vs -438.1%, a 191.4% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 7.6%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 9.8%).
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
DOMH vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $57.2M |
| Net Profit | $-131.8M | $-141.2M |
| Gross Margin | — | — |
| Operating Margin | -8.9% | -70.5% |
| Net Margin | -438.1% | -246.8% |
| Revenue YoY | 220.4% | 7.6% |
| Net Profit YoY | -12426.2% | -2774.3% |
| EPS (diluted) | $-6.94 | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $57.2M | ||
| Q3 25 | $50.8M | $56.3M | ||
| Q2 25 | $34.1M | $52.6M | ||
| Q1 25 | $8.1M | $50.0M | ||
| Q4 24 | $9.4M | $53.2M | ||
| Q3 24 | $4.0M | $47.7M | ||
| Q2 24 | $6.2M | $50.5M | ||
| Q1 24 | $1.4M | $47.5M |
| Q4 25 | $-131.8M | $-141.2M | ||
| Q3 25 | $125.2M | $-22.6M | ||
| Q2 25 | $16.6M | $-27.2M | ||
| Q1 25 | $-32.5M | $-29.5M | ||
| Q4 24 | $1.1M | $-4.9M | ||
| Q3 24 | $-4.2M | $-5.3M | ||
| Q2 24 | $-6.1M | $-4.5M | ||
| Q1 24 | $-5.4M | $-4.1M |
| Q4 25 | -8.9% | -70.5% | ||
| Q3 25 | -3.1% | -55.6% | ||
| Q2 25 | -57.0% | -73.2% | ||
| Q1 25 | -394.6% | -82.0% | ||
| Q4 24 | 0.4% | -19.3% | ||
| Q3 24 | -79.1% | -23.1% | ||
| Q2 24 | -44.3% | -20.1% | ||
| Q1 24 | -205.2% | -19.5% |
| Q4 25 | -438.1% | -246.8% | ||
| Q3 25 | 246.4% | -40.1% | ||
| Q2 25 | 48.7% | -51.7% | ||
| Q1 25 | -400.5% | -58.9% | ||
| Q4 24 | 11.4% | -9.2% | ||
| Q3 24 | -104.2% | -11.2% | ||
| Q2 24 | -99.1% | -9.0% | ||
| Q1 24 | -398.0% | -8.7% |
| Q4 25 | $-6.94 | $-2.40 | ||
| Q3 25 | $7.27 | $-0.38 | ||
| Q2 25 | $1.12 | $-0.46 | ||
| Q1 25 | $-3.02 | $-0.50 | ||
| Q4 24 | $0.21 | $-0.09 | ||
| Q3 24 | $-0.67 | $-0.09 | ||
| Q2 24 | $-1.01 | $-0.08 | ||
| Q1 24 | $-0.91 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $327.2M |
| Total Assets | $112.9M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $84.9M | ||
| Q3 25 | $176.2M | $70.0M | ||
| Q2 25 | $28.2M | $81.0M | ||
| Q1 25 | $18.9M | $111.8M | ||
| Q4 24 | $8.2M | $102.3M | ||
| Q3 24 | $7.2M | $100.5M | ||
| Q2 24 | $12.1M | $103.0M | ||
| Q1 24 | $7.1M | $125.2M |
| Q4 25 | $69.4M | $327.2M | ||
| Q3 25 | $210.2M | $466.0M | ||
| Q2 25 | $88.6M | $486.3M | ||
| Q1 25 | $42.4M | $511.4M | ||
| Q4 24 | $39.9M | $538.5M | ||
| Q3 24 | $38.3M | $541.2M | ||
| Q2 24 | $42.4M | $542.5M | ||
| Q1 24 | $47.7M | $544.0M |
| Q4 25 | $112.9M | $488.9M | ||
| Q3 25 | $223.4M | $601.1M | ||
| Q2 25 | $109.3M | $624.7M | ||
| Q1 25 | $52.3M | $631.9M | ||
| Q4 24 | $47.1M | $656.2M | ||
| Q3 24 | $43.4M | $645.1M | ||
| Q2 24 | $49.1M | $651.4M | ||
| Q1 24 | $52.2M | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-29.4M |
| Free Cash FlowOCF − Capex | — | $-29.5M |
| FCF MarginFCF / Revenue | — | -51.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-29.4M | ||
| Q3 25 | $-4.9M | $-31.6M | ||
| Q2 25 | $-353.0K | $-15.3M | ||
| Q1 25 | $1.2M | $-33.1M | ||
| Q4 24 | $-16.7M | $-1.8M | ||
| Q3 24 | $-4.7M | $-14.6M | ||
| Q2 24 | $1.4M | $-6.9M | ||
| Q1 24 | $-8.6M | $7.6M |
| Q4 25 | — | $-29.5M | ||
| Q3 25 | — | $-31.8M | ||
| Q2 25 | — | $-15.6M | ||
| Q1 25 | — | $-33.6M | ||
| Q4 24 | — | $-2.0M | ||
| Q3 24 | — | $-14.7M | ||
| Q2 24 | — | $-7.0M | ||
| Q1 24 | — | $7.6M |
| Q4 25 | — | -51.6% | ||
| Q3 25 | — | -56.5% | ||
| Q2 25 | — | -29.6% | ||
| Q1 25 | — | -67.1% | ||
| Q4 24 | — | -3.8% | ||
| Q3 24 | — | -30.9% | ||
| Q2 24 | — | -13.9% | ||
| Q1 24 | — | 15.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | — | 0.4% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | — | ||
| Q2 25 | -0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -15.65× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
